Skip to main content
Clinical Trials/NCT05933122
NCT05933122
Recruiting
Not Applicable

Study of the Prevalence of Sexual Dysfunction in Women After Rectal Cancer Surgery and Analysis of the Impact of a Sexologist Intervention

University Hospital, Limoges6 sites in 1 country144 target enrollmentApril 3, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Tumor
Sponsor
University Hospital, Limoges
Enrollment
144
Locations
6
Primary Endpoint
Number and proportion of women with sexual dysfunction defined as a total FSFI
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

RectSexQoL is a study aiming at determining the prevalence of female sexual dysfunction after rectal cancer surgery. It has the goal as well to analyse the impact of an intervention given by a sexologist to such patients.

Detailed Description

The treatment of rectal cancer is multimodal combining surgery, chemotherapy and radiotherapy. Each therapeutic tool may affect the sexual life of treated patients. The incidence of sexual dysfunction in patients with rectal cancer varies according to literature from 5 to 88%. This may be due to the lack of a common definition relating to sexual dysfunction making it difficult to compare results. On the other hand, it should be noted that all of the work related to sexual dysfunction after treatment for rectal cancer is mainly interested in men. The sexual well-being of women treated for rectal cancer is based on the assessment and management of their sexual functions as well as that of their overall sexual health in a personalized manner. The establishment of a sexology consultation before and after such a surgical procedure could improve the sexual functions as well as the sexual well-being of these women. The main aim of our study is to evaluate the prevalence of sexual dysfunctions at M-1 (before treatment) in the two cohorts "here" and "elsewhere" in the context of surgery for rectal cancer in females. The second aim will be to determine the impact of sexology consultation in the cohort "here" in comparison to the standart cohort without any intervention called "elsewhere".

Registry
clinicaltrials.gov
Start Date
April 3, 2024
End Date
October 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
University Hospital, Limoges
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of stage I-III rectal adenocarcinoma or rectosigmoid junction with anastomosis less than 15 cm from the anal margin
  • Surgical management, preceded or not by Radio-chemotherapy, with restoration of continuity
  • Age : over 18
  • Proficiency in French or English

Exclusion Criteria

  • Current pregnancy
  • Significant cognitive/psychiatric disorders
  • Guardianship

Outcomes

Primary Outcomes

Number and proportion of women with sexual dysfunction defined as a total FSFI

Time Frame: Month -1

Number and proportion of women with sexual dysfunction defined as a total FSFI ("Female Sexual Function Index") score greater than 26.55 at Month -1 (before any treatment) in the context of surgery for rectal cancer

Secondary Outcomes

  • Number and proportion of women with sexual dysfunction defined as a total FSFI score greater than 26.55 at Month 6 and Month 12 after usual or specific management in the context of surgery for rectal cancer(Month 12)
  • Change in the score of the "satisfaction" dimension of the FSFI scale between Month -1, Month 6 and Month 12(Month 12)
  • Differences (Month 6 - Month -1 and Month 12 - Month 6) in the score of the "satisfaction" dimension of the FSFI scale (Q14-Q16) between the groups with and without treatment by a sexologist (cohort here vs. elsewhere)(Month 12)

Study Sites (6)

Loading locations...

Similar Trials